Chronic
Inflammatory
Demyelinating
Polyneuropathy (CIDP) Treatment Market –
Trends and Opportunity Analysis, 2018 – 2026
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder
which causes paralysis (impairment of sensory function in limbs). It occurs due to the
inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering
(myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading
to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an
immunosuppressant, plasma exchange, and intravenous immunoglobulin therapy.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2609
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Drivers
Increasing drug approvals by regulatory authorities is expected to boost the global chronic
inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in
March 2017, CSL Behring received U.S. Food and Drug Administration (FDA) approval for
Privigen, an immunoglobulin therapy for the treatment of chronic inflammatory demyelinating
polyneuropathy (CIDP) disorder. 207 patients were treated with Privigen for 13 weeks and 73%
out of these 207 patients responded to it in clinical trials. Furthermore, in March 2018, CSL
Behring received U.S. FDA approval for Hizentra, which is a type of subcutaneous
immunoglobulin therapy that prevents relapsing neuromuscular disability. It offers a convenient
treatment type, in which patients can infuse themselves. The approval was based on the phase
III results of the clinical trial. These factors are expected to propel the global chronic
inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
Moreover, there are several potential drugs in the pipeline for the treatment of chronic
inflammatory demyelinating polyneuropathy (CIDP). For instance, in January 2016, Shire plc,
began clinical trials of HyQvia for treatment of chronic inflammatory demyelinating
polyneuropathy (CIDP) disorder. HyQvia is a type of intravenous immunoglobulin therapy
approved for the treatment of primary immunodeficiency and is currently in phase III of clinical